vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and Inventiva S.A. (IVA). Click either name above to swap in a different company.
Inventiva S.A. is the larger business by last-quarter revenue ($5.1K vs $1.9K, roughly 2.6× Aspire Biopharma Holdings, Inc.). Aspire Biopharma Holdings, Inc. runs the higher net margin — -95337.1% vs -961352.9%, a 866015.8% gap on every dollar of revenue.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
ASBP vs IVA — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $5.1K |
| Net Profit | $-1.9M | $-49.0M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | -961352.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | — |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $11.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $-85.4M |
| Total Assets | $2.4M | $42.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 24 | — | $11.0M |
| Q3 25 | $-11.5M | — | ||
| Q2 24 | — | $-85.4M |
| Q3 25 | $2.4M | — | ||
| Q2 24 | — | $42.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.1M | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
